Scope
NICE NG126 addresses early-pregnancy pain and bleeding, pregnancy of unknown location, miscarriage and tubal ectopic pregnancy. This selected summary emphasizes diagnostic safeguards, strict treatment eligibility and follow-up, and includes the updated gestation-specific anti-D recommendations. Clinical deterioration overrides an apparently reassuring scan or biochemical trend.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognize ectopic pregnancy and urgent deterioration
- Send a haemodynamically unstable patient, or someone with concerning pain or bleeding, directly for emergency assessment. Ectopic pregnancy can present atypically and must be considered even without known risk factors. [1]
- A positive pregnancy test with abdominal pain and tenderness, pelvic tenderness or cervical-motion tenderness needs immediate early-pregnancy or gynaecology assessment. Refer bleeding or other early-pregnancy symptoms with pain, gestation at least 6 weeks or uncertain dates, with urgency determined clinically. [1]
Avoid diagnosing miscarriage from an uncertain scan
- Offer transvaginal ultrasound to establish pregnancy location, fetal pole and heartbeat. Explain that a single scan can be wrong, particularly very early; if transvaginal scanning is unacceptable, offer transabdominal scanning and explain its limitations. [1]
- On transvaginal ultrasound with no heartbeat, a crown–rump length below 7 mm requires a repeat scan at least 7 days later before diagnosis; at 7 mm or more, obtain a second opinion and/or a repeat scan at least 7 days later. [1]
- On transvaginal ultrasound with no fetal pole, repeat after at least 7 days if the mean sac diameter is below 25 mm; at 25 mm or more, obtain a second opinion and/or repeat after at least 7 days. Corresponding inconclusive transabdominal findings require a minimum 14-day repeat interval. [1]
Let symptoms override reassuring biochemical trends
- Treat pregnancy of unknown location as potentially ectopic until location is established. Do not use hCG to locate the pregnancy or serum progesterone to distinguish viability or ectopic pregnancy. Prioritize changing symptoms over prior results and provide round-the-clock emergency-access instructions. [1]
- For pregnancy of unknown location, obtain 2 hCG measurements as close as possible to 48 hours apart, never earlier. A rise greater than 63% suggests developing intrauterine pregnancy but does not exclude ectopic pregnancy: offer a scan 7–14 days later and consider an earlier scan if hCG is at least 1,500 IU/L. [1]
- For pregnancy of unknown location with an hCG fall greater than 50% after 48 hours, arrange a urine test 14 days after the second blood test; a positive result needs review within 24 hours. A fall below 50% or rise below 63% also requires clinical review within 24 hours. [1]
Separate threatened, missed and incomplete miscarriage
- Offer vaginal micronised progesterone 400 mg twice daily for bleeding in a scan-confirmed intrauterine pregnancy when there has been a previous miscarriage. If fetal heartbeat is confirmed, continue until 16 completed weeks; this is not a blanket treatment for all early-pregnancy bleeding. [1]
- For confirmed miscarriage, use 7–14 days of expectant management first-line, unless bleeding risk, vulnerability to blood loss, infection or previous traumatic pregnancy experience favours another option. Offer medical management if expectant care is unacceptable. [1]
- After apparently completed expectant miscarriage management, provide a urine test for 3 weeks after miscarriage and review a positive result. If pain or bleeding never starts, persists or increases after the observation period, offer repeat scanning and discuss all management options. [1]
- For medical management of missed miscarriage, offer oral mifepristone 200 mg followed 48 hours later by misoprostol 800 micrograms vaginally, orally or sublingually, unless the gestational sac has already passed. Provide analgesia and antiemetics as needed. [1]
- For incomplete miscarriage, use a single misoprostol dose of 600 micrograms vaginally, orally or sublingually; 800 micrograms is an alternative for protocol alignment. Do not offer mifepristone for incomplete miscarriage. [1]
- After medical miscarriage treatment, arrange contact if bleeding has not started within 48 hours of misoprostol and provide a urine test at 3 weeks, advising earlier return if symptoms worsen. Review positive tests for retained, molar or ectopic pregnancy; persistent heavy bleeding, pelvic pain or fever still warrants assessment despite a negative test. [1]
- When surgical miscarriage management is appropriate, offer a choice of outpatient or clinic manual vacuum aspiration under local anaesthesia or theatre management under general anaesthesia. Provide information about the procedure, recovery and alternatives. [1]
Match tubal ectopic treatment to strict eligibility and follow-up
- Offer expectant care as an option for a stable, pain-free patient with tubal ectopic pregnancy below 35 mm, no visible heartbeat, hCG at most 1,000 IU/L and ability to attend follow-up. Consider it with the same conditions when hCG is above 1,000 but below 1,500 IU/L. [1]
- During expectant management of tubal ectopic pregnancy, repeat hCG on days 2, 4 and 7. If each result falls at least 15% from its predecessor, continue weekly until below 20 IU/L; an insufficient fall, plateau or rise requires clinical review and senior advice. [1]
- Offer systemic methotrexate for confirmed unruptured tubal ectopic pregnancy with no significant pain, mass below 35 mm, no heartbeat, hCG below 1,500 IU/L, no intrauterine pregnancy and reliable follow-up. At the first visit, definitive ectopic diagnosis and exclusion of viable intrauterine pregnancy are essential. [1]
- For ectopic pregnancy with hCG at least 1,500 but below 5,000 IU/L, offer a choice of methotrexate or surgery when there is no significant pain, an unruptured mass below 35 mm without heartbeat, no intrauterine pregnancy and reliable follow-up. Explain the greater chance of further intervention after methotrexate and urgent admission if deterioration occurs. [1]
- Offer first-line surgery for ectopic pregnancy when follow-up after methotrexate is unreliable, significant pain is present, the mass is at least 35 mm, a fetal heartbeat is visible or hCG is at least 5,000 IU/L. [1]
- After methotrexate for ectopic pregnancy, measure hCG on days 4 and 7, then weekly until negative; a plateau or rise requires reassessment for further treatment. [1]
Apply the updated gestation-specific anti-D guidance
- NICE does not offer anti-D prophylaxis for ectopic pregnancy, miscarriage or threatened miscarriage up to and including 11+6 weeks. When ultrasound and menstrual dates disagree, use ultrasound dating for this decision. [1]
- For RhD-negative patients at 12+0–12+6 weeks, offer at least 250 IU (50 micrograms) anti-D with medical or surgical management of ectopic pregnancy or miscarriage. Consider the same minimum dose for threatened miscarriage with heavy or recurrent bleeding. [1]
Provide sensitive care and a route back to help
- Give sensitive, individualized information about treatment, recovery, fertility and support services, with clear emergency contacts. After pregnancy loss, offer follow-up with a professional of the person’s choice. [1]
Limitations and use
- This is selected first-trimester guidance, not a complete ultrasound interpretation, resuscitation, methotrexate prescribing or surgical protocol. Treatment requires confirmed diagnosis, contraindication assessment, reliable follow-up and access to emergency care.
- The hCG trend rules retain the source’s strict inequalities; they do not establish new rules for unlisted exact-boundary results. Symptoms and senior review govern uncertain or changing presentations.
- The anti-D statements reflect this updated NICE source and its specified gestational window. Later gestations, different sensitising events, local policy and product availability require separate guidance.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Ectopic pregnancy and miscarriage: diagnosis and initial management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 17 April 2019
- Publisher’s latest update
- 17 June 2026
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.